source clustersSource Clusters is the single source of information on regional development in the life sciences sector worldwide.

With content providing broad overviews as well as in-depth coverage of business development trends, company activities, life science cluster collaborations, multi-partner scientific projects and its extensive news coverage, Source Clusters presents the latest management, research, technology and regional development information serving the needs of executives in the internationally growing life sciences sector.

Source Clusters is the essential resource for companies, incubators, science parks, clusters and regional development agencies looking to find a new location or attract new business and exploit new opportunities across the life sciences sector.

Avacta agrees Affimer reagent licensing deal with New England Biolabs

Avacta logo 7.7.18New England Biolabs logo 14.11.18Avacta Group plc, the developer of Affimer biotherapeutics and reagents, has agreed a commercial licence with Ipswich, Massachusetts, USA based New England Biolabs (NEB), a company specialising in the discovery and production of enzymes for molecular biology applications, to commercialise a product using Affimer technology in both life science research and diagnostics assays.

Avacta and NEB have been collaborating to develop Affimers to combine with NEB’s reagents and Avacta has identified Affimers that specifically inhibit certain NEB proprietary enzymes to provide modulation of their activity in response to temperature. Unlike alternative enzyme inhibitors, Affimers can be fine-tuned to switch at the right temperature without having a negative effect on overall assay performance. NEB is in the final stages of product testing and the two companies have agreed terms under which NEB will commercialise the combined product. The two companies expect to continue the collaboration to generate Affimer tools and inhibitors to other enzymes, and thus enable the development of further products.

Full financial details of the agreement are not being disclosed, but Avacta will receive a royalty on product sales, which may occur as soon as 2019.

For further information about Avacta Group plc visit and for further information about New England Biolabs visit

Last modified onWednesday, 14 November 2018 09:27

Latest from Tom Mulligan